Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • Refractive
  • Cataract
  • Glaucoma
  • Cornea
  • Retina
  • Practice Mgmt.
  • OTE
  • Job Board
MJH Life Sciences

SUBSCRIBE: Print / Digital / eNewsletter

Pharmacy

CK technique focuses on presbyopia

November 1, 2006

Columbia, SC—The Light Touch technique of conductive keratoplasty (CK, Refractec), developed by refractive specialist Henry L. "Rick" Milne, MD, shows promise in the correction of near vision in patients with presbyopia, explained Dr. Milne.

  • READ >>

Variable dosing of ranibizumab investigated for treatment of neovascular AMD

November 1, 2006

Miami—One year into a 2-year study using an optical coherence tomography (OCT)-guided variable dosing regimen for ranibizumab (Lucentis, Genentech) for neovascular age-related macular degeneration (AMD), two key findings have emerged, according to lead investigator Philip Rosenfeld, MD, PhD.

  • READ >>

Dr. Hnik joins iCo Therapeutics as CMO

November 1, 2006

Vancouver, British Columbia—Peter Hnik, MD, MHS, has been named chief medical officer of iCo Therapeutics Inc. The biotechnology company is developing pre-existing drugs for a range of new conditions affecting isolated biologic environments—areas such as the eye, spinal cord, and joints, where locally administered application of these therapies would have minimal systemic distribution and fewer safety issues.

  • READ >>

Lux Biosciences, Rutgers enter agreement

October 31, 2006

Lux Biosciences Inc., a privately held biotechnology company specializing in ophthalmic diseases, announced it has entered into an exclusive license agreement with Rutgers, The State University of New Jersey, to access its polyarylate patent estate.

  • READ >>

ISTA gains license for conjunctivitis formulation

October 31, 2006

ISTA Pharmaceuticals acquired from Senju Pharmaceuticals an exclusive North American license to an eye-drop formulation containing bepotastine, an investigational ophthalmic treatment for allergic conjunctivitis. This is ISTA Pharmaceuticals' first license for the ophthalmic allergy field.

  • READ >>

FDA approves B&L plasma treatment of GP contact lenses

October 15, 2006

Las Vegas—Bausch & Lomb has received U.S. FDA approval to add a cold oxygen plasma treatment to the manufacturing process of gas permeable (GP) contact lenses made with Boston materials. B&L made the announcement recently at the American Optometric Association Congress and Annual American Optometric Student Association Conference.

  • READ >>

Synthetic inlays in early study for refractive correction

October 15, 2006

Sydney, Australia—The first synthetic polymer corneal inlays implanted in humans appear to be biocompatible with corneal tissue and represent a safe, biologically acceptable alternative to other forms of refractive surgery, according to observations made over an 18-month period, said Deborah F. Sweeney, B Optom, PhD.

  • READ >>

ExonHit, Allergan extend collaboration

October 15, 2006

Paris—ExonHit Therapeutics SA, a drug and diagnostic discovery company, has extended its strategic collaboration with Allergan Inc., a global specialty pharmaceutical company, to identify, develop, and commercialize drugs targeted at the treatment of ophthalmologic conditions, neurodegenerative diseases, and pain, based on positive preclinical trial results.

  • READ >>

BAK-free travoprost formulation approved

October 15, 2006

Alcon Laboratories has received FDA approval to market a new, benzalkonium chloride (BAK)-free formulation of travoprost 0.004% ophthalmic solution (Travatan Z). Prescribers can expect the product to be available by the end of the month.

  • READ >>

Athenagen begins testing ATG003

October 15, 2006

San Francisco—Athenagen Inc., a privately held biopharmaceutical company, has begun phase I clinical testing of ATG003, its topical eye drop therapy for age-related macular degeneration (AMD).

  • READ >>

Pages

  • « first
  • ‹ previous
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Dry Eye Awareness
  • Ocular Surface Disease
  • Wet AMD
  • IOL Advances
  • Therapeutic Cataract & Refractive
Shifting The Paradigm for Retinal Disease Management: The Value of Modern Electroretinography
Video on CATALYS® Laser System presented by Johnson & Johnson
Video on WHITESTAR SIGNATURE® PRO System by Johnson & Johnson
CME Activities
DEXYCU® (dexamethasone intraocular suspension) 9% Case Study Series

Current Issue

Ophthalmology Times: December 2019
Dec 10, 2019 Vol 44 No 20
Digital Edition
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".